RAPID-1 DFU Clinical Trial

Recruitment has commenced for the RAPID -1 DFU Phase 2b randomised controlled clinical trial to investigate the safety and efficacy of the RAPID™ Biodynamic Haematogel treatment for patients with chronic diabetic foot ulcers in comparison with usual and customary care.

All regulatory approvals secured [MHRA, REC, NIHR, HRA] and recruitment commenced.

Trial details to be published in leading Journals.

Previous Publications

Pilot Study

In September 2014, the Company completed a Diabetic Foot Ulcer Pilot Study at The Royal London Hospital, Barts Health NHS Trust, treating patients with severe diabetic wounds at high risk of limb amputation. The proprietary treatment resulted in preventing 14 out of 15 amputations, as published in the British Journal of Surgery, February 2015.

Martin T, Kyriakides CK, Sarkar S. Platelet Rich Plasma (PRP) is an Adjunct for the Accelerated Closure of High-Risk Diabetic Foot Wounds. British Journal of Surgery Feb 2015 102; S2: p24  See study 

Summary of the results

“The use of autologous PRP is associated with rapid wound closure and low amputation rates”

“Significant decrease in wound volume with an average reduction in the size of 75.5% and achieving wound closure in all but one patient”

Average time taken to complete wound closure was 17.9 days therefore rapidly reducing the risk of proceeding to major amputation and shortening hospital admission”